日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

6-Phosphogluconate dehydrogenase promotes mitochondrial fusion and immune suppression in tumor-associated monocytic suppressor cells.

6-磷酸葡萄糖酸脱氢酶促进肿瘤相关单核细胞抑制细胞的线粒体融合和免疫抑制。

Daneshmandi Saeed, Yan Qi, Gomez Eduardo Cortes, Choi Jee Eun, Katsuta Eriko, Gharib Ehsan, Singh Prashant K, Higashi Richard M, Lane Andrew N, Fan Teresa W-M, Wang Jianmin, Repasky Elizabeth A, McCarthy Philip L, Mohammadpour Hemn

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

解析局灶性病变肿瘤微环境中中性粒细胞的动态变化,以克服多发性骨髓瘤的免疫抑制

Rivera, Joshua; Yan, Qi; Daneshmandi, Saeed; Lannes, Romain; Katsuta, Eriko; Choi, JeeEun; Singh, Prashant; Belal, Ahmed; Alberico, Ronald; Lund, Ian; Schaefer, Megan; Hassan, Hamza; Parker, Sarah; Anderson, Kenneth C; Munshi, Nikhil C; Samur, Mehmet; McCarthy, Philip L; Hillengass, Jens; Mohammadpour, Hemn

Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma

B细胞成熟抗原(BCMA)NEX-T®嵌合抗原受体(CAR)T细胞疗法CC-98633/BMS-986354在接受过三线抗肿瘤治疗的多发性骨髓瘤患者中的I期临床试验

Ravi, Gayathri; Richard, Shambavi; Kumar, Shaji; Atrash, Shebli; Liedtke, Michaela; Kaur, Gurbakhash; Derman, Benjamin; Bergsagel, P Leif; Mailankody, Sham; McCarthy, Philip; Shrestha, Alok; Kelly, Lisa M; Ly, Thomas; Das, Sharmila; Thorpe, Jerill; Maier, Alison; Varun, Divya; Navarro, Garnet; Burgess, Michael R; Hege, Kristen; Koegel, Ashley K; Costa, Luciano J

Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702

尿液无反应标准预测多发性骨髓瘤的无进展生存期:BMT CTN 0702 的事后分析

Banerjee, Rahul; Fritz, Amber R; Akhtar, Othman S; Freeman, Ciara L; Cowan, Andrew J; Shah, Nina; Landau, Heather J; Kumar, Shaji K; Vogl, Dan T; Efebera, Yvonne A; McCarthy, Philip L; Vesole, David H; Mendizabal, Adam; Krishnan, Amrita Y; Somlo, George; Stadtmauer, Edward A; Pasquini, Marcelo C

Targeting the pentose phosphate pathway mitigates graft-versus-host disease by rewiring alloreactive T cell metabolism.

靶向磷酸戊糖途径可通过重塑同种异体反应性 T 细胞代谢来减轻移植物抗宿主病。

Daneshmandi Saeed, Ko Eun, Yan Qi, Choi Jee Eun, Singh Prashant K, Higashi Richard M, Lane Andrew N, Fan Teresa Wm, Qiu Jingxin, Hani Sophia, Hippen Keli L, Wang Jianmin, McCarthy Philip L, Blazar Bruce R, Mohammadpour Hemn

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival

自体造血干细胞移植和来那度胺维持治疗1年后多发性骨髓瘤的微小残留病灶状态与长期总生存期相关

Pasquini, Marcelo C; Wallace, Paul K; Logan, Brent; Kaur, Manmeet; Tario, Joseph D; Howard, Alan; Zhang, Yali; Brunstein, Claudio; Efebera, Yvonne; Geller, Nancy; Giralt, Sergio; Hari, Parameswaran; Horowitz, Mary M; Koreth, John; Krishnan, Amrita; Landau, Heather; Somlo, George; Shah, Nina; Stadtmauer, Edward; Vogl, Dan T; Vesole, David H; McCarthy, Philip L; Hahn, Theresa

Exportin 1 governs the immunosuppressive functions of myeloid-derived suppressor cells in tumors through ERK1/2 nuclear export

Exportin 1 通过 ERK1/2 核输出调控肿瘤中髓系来源抑制细胞的免疫抑制功能

Daneshmandi, Saeed; Yan, Qi; Choi, Jee Eun; Katsuta, Eriko; MacDonald, Cameron R; Goruganthu, Mounika; Roberts, Nathan; Repasky, Elizabeth A; Singh, Prashant K; Attwood, Kristopher; Wang, Jianmin; Landesman, Yosef; McCarthy, Philip L; Mohammadpour, Hemn

Myeloid-derived suppressor cell mitochondrial fitness governs chemotherapeutic efficacy in hematologic malignancies.

髓系来源的抑制细胞线粒体功能决定了血液系统恶性肿瘤的化疗疗效

Daneshmandi Saeed, Choi Jee Eun, Yan Qi, MacDonald Cameron R, Pandey Manu, Goruganthu Mounika, Roberts Nathan, Singh Prashant K, Higashi Richard M, Lane Andrew N, Fan Teresa W-M, Wang Jianmin, McCarthy Philip L, Repasky Elizabeth A, Mohammadpour Hemn

Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401

更正:树突状细胞/骨髓瘤融合疫苗联合来那度胺维持治疗多发性骨髓瘤一线自体造血干细胞移植后的随机II期试验:BMT CTN 1401

Chung, David J; Shah, Nina; Wu, Juan; Logan, Brent; Bisharat, Lina; Callander, Natalie; Cheloni, Giulia; Anderson, Kenneth; Chodon, Thinle; Dhakal, Binod; Devine, Steve; Dutt, Poorvi Somaiya; Efebera, Yvonne; Geller, Nancy; Ghiasuddin, Haider; Hematti, Peiman; Holmberg, Leona; Howard, Alan; Johnson, Bryon; Karagkouni, Dimitra; Lazarus, Hillard M; Malek, Ehsan; McCarthy, Philip; McKenna, David; Mendizabal, Adam; Nooka, Ajay; Munshi, Nikhil; O'Donnell, Lynn; Patel, Krina; Rapoport, Aaron P; Reese, Jane; Rosenblatt, Jacalyn; Soiffer, Robert; Stroopinsky, Dina; Uhl, Lynne; Vlachos, Ioannis S; Waller, Edmund K; Young, James W; Pasquini, Marcelo C; Avigan, David

A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help

健全的质量基础设施是安全有效地输送免疫效应细胞的关键:FACT 调查如何提供帮助

Curran, Kevin J; Nikiforow, Sarah; Bachier, Carlos; Hsu, Yen-Michael; Maloney, David; Maus, Marcela V; McCarthy, Philip; Porter, David; Shi, Patricia; Shpall, Elizabeth J; William, Basem; Wacker, Kara; Warkentin, Phyllis; Heslop, Helen E